300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Non Profit
Clean Energy
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Social Impact
Retail
Oil and Gas
Payments
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Facebook
Renewable Energy
Software
Blockchain
Theatre
Beauty
Medical
Web3
Recruiting
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Fashion
Infrastructure
Social
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Tunisia
Taiwan
Zimbabwe
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Bangladesh
Spain
Angola
Europe
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Peter Dudek, Partner at MRL Ventures Fund

Peter Dudek

Partner @ MRL Ventures Fund

Cambridge, United States

Peter Dudek is a partner MRL Ventures Fund at Merck.

Total investments:
5
Last investment:
Lead investor:
0%

Last updated:

Industries Peter Dudek invests in

BiotechnologyHealth CareTherapeuticsMedicalLife Science

Stages Peter Dudek invests in

Series BSeries CSeries A

Countries Peter Dudek invests in

United States

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biotechnology 3 (60%)
  • Health Care 2 (40%)
  • Therapeutics 2 (40%)
  • Medical 1 (20%)
  • Life Science 1 (20%)
See all 6 industries →

Stage

  • Series B 2 (40%)
  • Series C 2 (40%)
  • Series A 1 (20%)

Investments

CompanyDescriptionRoundLinks
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. $30M / Series C / Sep 21, 2022
The company intended to focus on developing novel immune engagers. $55M / Series A / Oct 26, 2021
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. $12M / Series B / Mar 01, 2021
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of provenimmuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatmentXilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States. $95M / Series C / Feb 24, 2021
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of provenimmuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatmentXilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States. $100.5M / Series B / Mar 02, 2020

Co-Investors

MRL Ventures Fund

About MRL Ventures Fund

VC Fund · Cambridge, United States

The MRL Venture Fund is the Cambridge, MA – based independent venture capital investment group within Merck Research Laboratories, the R&D division of Merck & Co., Inc. MRL Ventures creates and/or invests in seed and early-stage therapeutics companies, based on translatable breakthrough science, with the potential to deliver highly differentiated new medicines to improve human health.

MRL Ventures Fund Contacts

NameEmailPhoneSocials
Peter Dudek
Peter Dudek Partner
Reza Halse
Reza Halse Partner

Sign up to unlock verified contacts

Unlock Contacts

See all 3 contacts →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Non Profit
Clean Energy
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Social Impact
Retail
Oil and Gas
Payments
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Facebook
Renewable Energy
Software
Blockchain
Theatre
Beauty
Medical
Web3
Recruiting
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Fashion
Infrastructure
Social
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Tunisia
Taiwan
Zimbabwe
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Bangladesh
Spain
Angola
Europe
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Peter Dudek invest in?

Peter Dudek invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Peter Dudek?

Public channels for Peter Dudek include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Peter Dudek last invest?

The most recent investment recorded for Peter Dudek closed in Sep 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Peter Dudek Peter Dudek Find email